Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.
Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.
复制标题
麻疹疫苗失败时的细胞免疫：尽管重新接种后血清抗体产生有限，但仍显示出麻疹抗原特异性淋巴增殖反应。
DOI：
10.1093/infdis/172.6.1591
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
DeSerres,G
中科院分区：
文献类型：
--
作者：
Ward,BJ;Boulianne,N;Ratnam,S;Guiot,MC;Couillard,M;DeSerres,G
在60名先前接种疫苗的受试者（9.4 ± 3.4岁）中，在再接种疫苗后1个月和6个月评价麻疹抗原特异性免疫应答，这些受试者的空斑减少中和（PRN）滴度<200）不可检测或较低。所有受试者的PRN滴度在1个月时均升高（590 ± 61;范围：129-2513），但66%的受试者在6个月时再次下降（214 ± 29;范围：30-794）。在6个月时，23例（38%）的PRN滴度低于保护性水平<120或临界值<200。在再接种前，对麻疹病毒抗原的抗增殖反应总体上较低（平均刺激指数[SI]，2.6 ± 0.4;范围，0.5-13.5），但在再接种后1个月（SI，14.8 ± 2.6;范围，1.4-80）和6个月（SI，9.4 ± 1.8;范围，1.1-87）时很容易检测到。在再接种前，10例（50%）PRN滴度低的受试者的SI ≥ 3。在再接种后6个月，18例PRN滴度> 200的受试者（78%）发生SI> 3。这些数据表明，在某些受试者中，接种疫苗和再接种疫苗后，对麻疹病毒的细胞反应可能比抗体滴度更好地持续。
Measles antigen-specific immune responses were evaluated 1 and 6 months after revaccination in 60 previously vaccinated subjects (9.4 ± 3.4 years of age) who had either undetectable or low plaque reduction neutralization (PRN) titers <200). PRN titers were increased in all subjects at 1 month (590 ± 61; range, 129–2513) but fell again in 66% of subjects by 6 months (214 ± 29; range, 30–794). At 6 months, 23 (38%) had subprotective <120) or borderline <200) PRN titers. Lymphoproliferative responses to measles virus antigens were low overall before revaccination (mean stimulation index [SI], 2.6 ± 0.4; range, 0.5–13.5) but were readily detectable at 1 (SI, 14.8 ± 2.6; range, 1.4–80) and 6 months after revaccination (SI, 9.4 ± 1.8; range, 1.1–87). Before revaccination, 10 of the subjects (50%) with low positive PRN titers had SIs ⩾3. At 6 months after revaccination, 18 subjects (78%) with PRN titers ⩽200 had SIs ⩾3. These data suggest that cellular responses to measles virus may be better sustained than antibody titers after vaccination and revaccination in some subjects.